Chris H. Takimoto
Independent DirectorDr. Chris H. Takimoto M.D., Ph.D., FACP, is Global Chief Medical Officer of South Texas Accelerated Research Therapeutics, LP. Dr. Takimoto has been an Independent Director of ALX Oncology Holdings Inc. since January 18, 2025. He serves as Member of Cancer Scientific Advisory Board at Thetis Pharmaceuticals LLC. He served as Chief Medical Officer at IGM Biosciences, Inc. since July 29, 2021 until October 2024. Dr. Takimoto serves as Member of Clinical Advisory Board at Rondo Therapeutics. Takimoto served as Chief Medical Officer of Forty Seven Inc. Dr. Takimoto serves as Director of Pharmacology and the Zachry Chair of Translational Research at the Institute for Drug Development. He is an expert in Phase I and early clinical development of cancer therapies. He served as Vice President of Experimental Medicine Early at Development Oncology at Janssen/J&J since September 2010 until January 2016. Dr. Takimoto served as Member of Clinical Advisory Board of Avalon Pharmaceuticals, Inc since January 2007. He joins IGM with experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences, Inc. From 2008 to 2010, Dr. Takimoto served as Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development. He has experience in industry and academia, including academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute and the Uniformed Services University of the Health Sciences. He also served as a Commissioned Officer in the U.S.Public Health Service. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University and an M.D. from Yale University School of Medicine.
Positions
- Company NameALX Oncology Holdings Inc.Stock CodeALXOPositionIndependent DirectorColleagues
- JWJason W. LettmannCEO & Director
- SGScott GarlandIndependent Chairman
- HSHarish ShantharamChief Financial Officer
- SWShelly WongSenior VP of Finance & Chief Accounting Officer
- BJBarbara J. KlenckeChief Medical Officer
- JEJeff E. KnightChief Development & Operating Officer
- RHRekha HemrajaniIndependent Director
- KTKeith T. FlahertyChair of the Scientific Advisory Board
